Syros Pharmaceuticals Inc (SYRS) Given Average Recommendation of “Buy” by Analysts

Shares of Syros Pharmaceuticals Inc (NASDAQ:SYRS) have received a consensus recommendation of “Buy” from the ten ratings firms that are covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, three have given a hold recommendation and six have issued a buy recommendation on the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $22.36.

SYRS has been the subject of a number of research analyst reports. Zacks Investment Research downgraded Syros Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, October 11th. Roth Capital initiated coverage on Syros Pharmaceuticals in a report on Monday, October 23rd. They issued a “neutral” rating and a $15.00 target price for the company. Piper Jaffray Companies reiterated an “overweight” rating and issued a $30.00 target price on shares of Syros Pharmaceuticals in a report on Tuesday, October 31st. Oppenheimer reiterated a “buy” rating and issued a $28.00 target price on shares of Syros Pharmaceuticals in a report on Thursday, December 7th. Finally, Cowen reiterated a “buy” rating on shares of Syros Pharmaceuticals in a report on Monday, December 11th.

Shares of Syros Pharmaceuticals (NASDAQ SYRS) traded down $0.06 on Friday, hitting $9.47. The stock had a trading volume of 322,207 shares, compared to its average volume of 316,049. Syros Pharmaceuticals has a 52 week low of $6.30 and a 52 week high of $24.38. The company has a market capitalization of $293.21 and a P/E ratio of -4.71.

Syros Pharmaceuticals (NASDAQ:SYRS) last issued its earnings results on Wednesday, November 8th. The company reported ($0.53) earnings per share for the quarter, hitting the Zacks’ consensus estimate of ($0.53). sell-side analysts anticipate that Syros Pharmaceuticals will post -2.12 EPS for the current fiscal year.

In other news, insider Jeremy P. Springhorn acquired 15,000 shares of the firm’s stock in a transaction dated Friday, December 15th. The stock was purchased at an average price of $9.08 per share, for a total transaction of $136,200.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Srinivas Akkaraju acquired 109,774 shares of the firm’s stock in a transaction dated Thursday, December 14th. The shares were purchased at an average price of $9.03 per share, with a total value of $991,259.22. The disclosure for this purchase can be found here. Over the last quarter, insiders acquired 334,198 shares of company stock valued at $3,127,458. 33.60% of the stock is currently owned by corporate insiders.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. GSA Capital Partners LLP bought a new stake in shares of Syros Pharmaceuticals during the third quarter valued at approximately $240,000. Cubist Systematic Strategies LLC bought a new stake in shares of Syros Pharmaceuticals during the third quarter valued at approximately $149,000. Schwab Charles Investment Management Inc. increased its holdings in shares of Syros Pharmaceuticals by 95.8% during the third quarter. Schwab Charles Investment Management Inc. now owns 41,709 shares of the company’s stock valued at $614,000 after acquiring an additional 20,409 shares in the last quarter. Citadel Advisors LLC bought a new stake in shares of Syros Pharmaceuticals during the third quarter valued at approximately $975,000. Finally, Trexquant Investment LP bought a new stake in shares of Syros Pharmaceuticals during the third quarter valued at approximately $282,000. Hedge funds and other institutional investors own 56.04% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This article was originally posted by American Banking News and is the property of of American Banking News. If you are reading this article on another domain, it was stolen and republished in violation of United States and international copyright and trademark law. The original version of this article can be read at https://www.americanbankingnews.com/2018/02/02/syros-pharmaceuticals-inc-syrs-given-average-recommendation-of-buy-by-analysts.html.

Syros Pharmaceuticals Company Profile

Syros Pharmaceuticals, Inc is a biopharmaceutical company. The Company offers a gene control platform designed to analyze the unexploited region of deoxyribonucleic acid (DNA) in human disease tissue to identify and drug targets linked to genomically defined patient populations. The Company is focused on developing treatments for cancer and immune-mediated diseases and is building a pipeline of gene control medicines.

Analyst Recommendations for Syros Pharmaceuticals (NASDAQ:SYRS)

Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply